Akero therapeutics, inc. (AKRO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-11,886

-15,611

-15,554

-7,228

-5,362

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

1,237

670

483

402

215

Non-cash lease expense

54

-

-

-

-

Net amortization of premiums and discounts on short-term investments

103

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-724

-590

1,794

-500

-197

Accounts payable

588

854

-1,597

881

-564

Accrued expenses and other current liabilities

-1,931

-

-

-

70

Net cash used in operating activities

-11,317

-11,649

-13,212

-5,322

-5,444

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of short-term marketable securities

24,781

-

-

-

-

Proceeds from maturities of short-term marketable securities

18,500

-

-

-

-

Net cash used in investing activities

-6,281

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of stock options

112

-

-

-

-

Proceeds from the disgorgment of stockholders' short-swing profits, net

52

-

-

-

-

Payment of initial public offering costs

-

-

-

-

720

Net cash provided by (used in) financing activities

164

115

-1,607

98,200

-720

Net decrease in cash, cash equivalents and restricted cash

-17,434

-83,047

-14,819

92,878

-6,164

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Net unrealizable gain on marketable securities

51

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses and other current liabilities

-

-

-

1,072

556